Imaging markers for Alzheimer disease: Which vs how

Revised diagnostic criteria for Alzheimer disease (AD) acknowledge a key role of imaging biomarkers for early diagnosis. Diagnostic accuracy depends on which marker (i.e., amyloid imaging, F-fluorodeoxyglucose [FDG]-PET, SPECT, MRI) as well as how it is measured (“metric”visual, manual, semiautomate...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Neurology 2013-07, Vol.81 (5), p.487-500
Hauptverfasser:	Frisoni, Giovanni B, Bocchetta, Martina, Chételat, Gael, Rabinovici, Gil D, de Leon, Mony J, Kaye, Jeffrey, Reiman, Eric M, Scheltens, Philip, Barkhof, Frederik, Black, Sandra E, Brooks, David J, Carrillo, Maria C, Fox, Nick C, Herholz, Karl, Nordberg, Agneta, Jack, Clifford R, Jagust, William J, Johnson, Keith A, Rowe, Christopher C, Sperling, Reisa A, Thies, William, Wahlund, Lars-Olof, Weiner, Michael W, Pasqualetti, Patrizio, DeCarli, Charles
Format:	Artikel
Sprache:	eng
Schlagworte:	Alzheimer Disease - diagnosis Alzheimer Disease - diagnostic imaging Alzheimer Disease - metabolism Biological and medical sciences Biomarkers - metabolism Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Fluorodeoxyglucose F18 Humans Magnetic Resonance Imaging - methods Medical sciences Neurology Radiography Tomography, Emission-Computed, Single-Photon - methods Views & Reviews
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!